In an IIT study conducted by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, the oral presentation highlighted the impressive safety, efficacy and persistence
The primary endpoint of objective response rate (ORR), confirmed by independent central review, was 60.9% with trastuzumab deruxtecan monotherapy (5.4mg/kg). Patients had a median of six prior therapies
The overall adverse event rate was comparable between tralokinumab and placebo during the trials, said the company. Tralokinumab is an investigational and fully human monoclonal antibody, which neutralises
Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. By recapitulating
Under the deal, Amneal will acquire a 65.1% stake in AvKARE and its related affiliate conducting business as R&S Northeast. AvKARE is a private label provider of generic
Aiming to attract global advanced biotechnology companies and research institutions, the City authorities will expand the industrial complex by adding the 11th Songdo industrial block with space of
ArQule is involved in the research and development of targeted therapeutics for the treatment of cancers and certain rare diseases. The company’s clinical-stage pipeline consists of four drug
The Independent Review Committee (IRC)-assessed results were presented at the 2019 American Society of Hematology Annual Meeting and Exhibition in Orlando, US. At a median follow-up of 28.3
Liso-cel is an investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy with a defined composition of purified CD8+ and CD4+ CAR T cells in relapsed/refractory large B-cell lymphomas.
Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.